Cell Therapy Manufacturing Market to Grow at a Steady CAGR of 12.0% During the Forecast Period

Consistent research and studies are driving the growth in Global Cell therapy manufacturing Market in the forecast period, 2022-2026.

According to TechSci Research report, “Cell Therapy Manufacturing Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026”, the global Cell Therapy Manufacturing market stood at USD3123.44 million in 2020 and is expected to grow at a steady CAGR of 12.00% during the forecast period on account of consistent research and studies related to cell therapies.

Cell therapy is a biotechnological procedure where viable cells are injected, grafted, or implanted into the human body that requires it as a part of a medical treatment. Major example can be understood using T-cells for the treatment of cancerous cells in the patient. The growing prevalence of various chronic diseases such as cancer, diabetes, and cardiovascular diseases has significantly increased the patient pool worldwide suffering from these diseases.

This in turn has significantly increased the demand for cell therapy manufacturing to find new treatments for the severe diseases. The expansion of the biopharmaceutical companies and biotechnological institutes is also supporting the growth of the global cell therapy manufacturing market in the upcoming five years.

Due to the sudden outbreak of COVID-19 pandemic, there has been a rapid increase in research and development of cell-based vaccines for the treatment of COVID-19. The presence of government and commercial funding agencies that are continually issuing grants to support projects at various phases of clinical trials can be ascribed to the growing number of ongoing clinical studies.

Apart of that, high cost of cellular therapies, dearth of skilled healthcare professionals, large scale manufacturing, stringent regulatory policies, and lack of awareness are some of the major factors that are inhibiting the growth of Cell Therapy Manufacturing Market.

Browse over 199 market data Figures and 4 market data Tables spread through 329 Pages and an in-depth TOC on "Global Cell Therapy Manufacturing Market"

https://www.techsciresearch.com/report/cell-therapy-manufacturing-market/7729.html

The global Cell Therapy Manufacturing market is segmented based on therapy, source of cell, scale of operation, source, application, end user, company, and regional distribution. Based on therapy, the market is segmented into T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies. Stem cell therapies is anticipated to hold the largest share of the market and dominate the segment in the next five years on account of rising research and development in the area.

Stem cells therapy is utilized for the cure of various chronic diseases and the consistent efforts to provide the best available treatment to the patients. Based on Source of Cell, the market is divided into Autologous and Allogenic. In terms of Scale of Operation, the market can be categorized into Preclinical, Clinical and Commercial. By Source, the market is fragmented into In-House Manufacturing and Contract Manufacturing.

Based on application, the market can be fragmented into Oncology, Cardiovascular Diseases, Orthopedic Diseases and Others. Oncology is expected to generate the maximum revenue shares in the market and assert its dominance over the market on the account of increasing research and studies in the field of oncology.

Moreover, the number of cases where the patient is suffering due to cancer or different type of cancers is also multiplying globally. Cell therapy is one of the most incorporated procedures for understanding the growth of cancerous cells and to overcome the cancer-causing cells in the body. The method is actively utilized and is thus aiding in the growth of the application.

Based on end user, the market can be segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes and Others.

Key market players in the global cell therapy Manufacturing market include:

·         Novartis AG

·         F. Hoffmann-La Roche AG

·         Gilead Sciences, Inc.

·         Thermo Fischer Scientific, Inc.

·         Catalent, Inc.

·         JSR Life Sciences LLC (KBI Biopharma Inc)

·         Waisman Center (Waisman Biomanufacturing)

·         Cell and Gene Therapy Catapult

·         Merck KGaA

·         Lonza Group

·         Oxford Biomedica Plc

·         WuXi AppTec

·         Charles River Laboratories International Inc.

·         Institut Merieux (ABL Inc.)

·         BioCentriq

·         Centre for Commercialization of Regenerative Medicine (CCRM)

·         Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)

·         Amgen Inc.

·         Bluebird Bio Inc.

·         Takeda Pharmaceutical Company Limited

Global Cell Therapy Manufacturing market is consolidated with a lot of well-established players having presence in several countries: with several domestic players possessing leadership in certain regions and countries, among others. Novartis AG holds the highest market share and is among the top five market players globally. F. Hoffmann La Roche AG ranks second in terms of market share in the overall cell therapy manufacturing market.

The company has a strong presence worldwide and a huge brand value. People in emerging countries are also aware of the presence, product portfolio and business of the company and are preferring it over other competitor brands.

Additionally, there are other prominent players such as Gilead Sciences, Inc., Thermo Fischer Scientific, Inc., Catalent, Inc., JSR Life Sciences LLC (KBI Biopharma Inc), Waisman Center (Waisman Biomanufacturing), Cell and Gene Therapy Catapult, Merck KGaA, Lonza Group and others, which are holding a significant position in the global Cell Therapy Manufacturing market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7729

Customers can also request for 10% free customization on this report.

“The Asia Pacific region will register the fastest CAGR during the forecast period. This can be attributed to the large and growing prevalence of chronic diseases such as Cancer, Cardiovascular Diseases, Diabetes, and others in the region especially in countries like China, India, and Japan. Additionally, supportive government policies and healthcare schemes launched by them across different countries in the region is expected to support market growth. For instance, in 2019, the Australian government announced an USD57 million investment into the manufacturing of CAR-T at the Peter MacCallum Cancer Center, ensuring that all stages of the CAR-T pathway are able to remain in Australia.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Cell Therapy Manufacturing Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026 Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Company  and By Region”, has evaluated the future growth potential of global Cell Therapy Manufacturing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global Cell Therapy Manufacturing market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/